ODACon™ Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies – PI3K Inhibitors is organized by i3 Health.
Breast cancer is the most diagnosed cancer in women, with hormone receptor (HR)–positive/human epidermal growth factor receptor 2 (HER2)–negative breast cancer being the most common subtype

ODACon™ Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies – PI3K Inhibitors is organized by i3 Health.
Breast cancer is the most diagnosed cancer in women, with hormone receptor (HR)–positive/human epidermal growth factor receptor 2 (HER2)–negative breast cancer being the most common subtype, making up 73% of cases (ACS, 2019)